NCT02921984View on ClinicalTrials.gov

Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

August 31, 2017

Conditions
Salivary Gland TumorsHead and Neck Cancer
Interventions
DRUG

Docetaxel

Docetaxel only: 80 mg/m2 on day one, every 21 days if

RADIATION

Intensity-modulated radiotherapy

a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks

DRUG

Pemetrexed

Pemetrexed only: 500 mg/m2 on day one, every 21 days

DRUG

Cisplatin

Cisplatin only: 70 mg/m2 on day one to day three, every 21 days

Trial Locations (1)

200011

Shanghai ninth people's hospital, Shanghai

All Listed Sponsors
lead

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER

NCT02921984 - Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors | Biotech Hunter | Biotech Hunter